Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
Public ClinicalTrials.gov record NCT00118703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
Study identification
- NCT ID
- NCT00118703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 350 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2005 (Type not available)
- Primary completion
- Feb 1, 2006 (Actual)
- Completion
- Feb 9, 2006 (Actual)
- Last update posted
- Aug 21, 2017
2005 – 2006
United States locations
- U.S. sites
- 40
- U.S. states
- 23
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35209 | — |
| GSK Investigational Site | Phoenix | Arizona | 85012 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Fresno | California | 93720 | — |
| GSK Investigational Site | Irvine | California | 92618 | — |
| GSK Investigational Site | Los Angeles | California | 90025 | — |
| GSK Investigational Site | Orange | California | 92868 | — |
| GSK Investigational Site | Paramount | California | 90723 | — |
| GSK Investigational Site | Sacramento | California | 95819 | — |
| GSK Investigational Site | San Francisco | California | 94102 | — |
| GSK Investigational Site | San Jose | California | 95128 | — |
| GSK Investigational Site | Walnut Creek | California | 94598 | — |
| GSK Investigational Site | Englewood | Colorado | 80112 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Sarasota | Florida | 34233 | — |
| GSK Investigational Site | Tallahassee | Florida | 32308 | — |
| GSK Investigational Site | Vero Beach | Florida | 32960 | — |
| GSK Investigational Site | Stockbridge | Georgia | 30281 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | Chicago | Illinois | 60632 | — |
| GSK Investigational Site | South Bend | Indiana | 46617 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71105 | — |
| GSK Investigational Site | Bethesda | Maryland | 20814 | — |
| GSK Investigational Site | Wheaton | Maryland | 20902 | — |
| GSK Investigational Site | North Dartmouth | Massachusetts | 02747 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | Jackson | Mississippi | 39202 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Brick | New Jersey | 8724 | — |
| GSK Investigational Site | Skillman | New Jersey | 08558 | — |
| GSK Investigational Site | Ithaca | New York | 14850 | — |
| GSK Investigational Site | Rochester | New York | 14618 | — |
| GSK Investigational Site | Sylvania | Ohio | 43560 | — |
| GSK Investigational Site | Blue Bell | Pennsylvania | 19422 | — |
| GSK Investigational Site | Providence | Rhode Island | 2906 | — |
| GSK Investigational Site | Chattanooga | Tennessee | 37421 | — |
| GSK Investigational Site | Dallas | Texas | 75231-4307 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | South Burlington | Vermont | 05403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00118703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2017 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00118703 live on ClinicalTrials.gov.